Tag: global primary biliary cholangitis market

  • Primary Biliary Cholangitis Market Forecast Reaching $1.6 Billion by 2029 at 9.9% CAGR

    Primary Biliary Cholangitis Market Forecast Reaching $1.6 Billion by 2029 at 9.9% CAGR

    Discover trends, market shifts, and competitive outlooks for the primary biliary cholangitis industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

    How Has the Primary Biliary Cholangitis Market Growth Performance Trended Historically, And What Lies Ahead?

    The market size for primary biliary cholangitis has seen swift expansion in the past few years. The projection is that it will escalate from $0.98 billion in 2024 to $1.09 billion in 2025, recording a compound annual growth rate (CAGR) of 11.8%. Factors contributing to this growth during the historic period include enhanced understanding of the disease, a surge in global healthcare spending, strategic partnerships in the healthcare domain, emphasis on patient advocacy, and government endeavors aimed at improving liver health.

    The market size for primary biliary cholangitis is forecasted to experience substantial growth in the coming years, reaching $1.6 billion by 2029 with a compound annual growth rate (CAGR) of 9.9%. The surge in the predicted period is affiliated with the growth of biomarker studies, global initiatives in managing rare diseases, enhanced cooperation in clinical trials, and a patient-focused healthcare system, as well as a rising demand for liver transplants. Key forthcoming trends encompass advancements in biomarker exploration, an increasing stress on non-invasive diagnostic methods, the intensified focus on immunomodulatory therapies, the incorporation of artificial intelligence (AI), patient-reported repercussions during clinical trials, the use of telemedicine for patient administration, emphasis on combination treatments, and the advent of therapies targeting fibrosis.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

    Which Major Market Drivers Are Expected to Boost the Growth Potential of the Primary Biliary Cholangitis Market?

    The escalating incidences of smoking are anticipated to stimulate the expansion of the primary biliary cholangitis market in the forthcoming period. Smoking, which is the process of inhaling and exhaling smoke from burning tobacco or other substances, is identified as a risk factor for liver diseases like PBC. It is predicted that amplified rates of smoking will result in a greater number of people seeking medical help for liver-associated problems. For example, as per Statistics Canada, a government agency of Canada, the production of cigarettes saw a 2.2% hike in July 2023 compared to June 2023. In addition, cigarette sales witnessed a 2.6% rise in June, hitting 1.4 billion units, more than what it was in May. Consequently, the growth in smoking habits will fuel the primary biliary cholangitis market’s growth.

    Growth in Primary Biliary Cholangitis Market Driven by Spurt in Liver Cancer Cases

     

    Which Key Market Segments Comprise the Primary Biliary Cholangitis Market and Drive Its Revenue Growth?

    The primary biliary cholangitis market covered in this report is segmented –

    1) By Treatment Type: Drugs, Liver Transplantation

    2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

    3) By End-Users: Specialty Clinics, Homecare, Other End-Users

    Subsegments:

    1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

    2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

    Which Areas Are Leading Regions in the Primary Biliary Cholangitis Market Expansion Across the Globe?

    North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Key Market Trends in thePrimary Biliary Cholangitis Market Over the Coming Years?

    Firms in the primary biliary cholangitis market are investing in the development of unique and specialized therapies, such as orphan drugs that combine obeticholic acid (OCA) and bezafibrates aimed at treating primary biliary cholangitis (PBC), to secure exclusive control of the market. The use of a drug designated as an orphan that combines OCA and bezafibrate serves as a more thorough and efficient method for managing PBC treatment, with the potential to enhance the quality of life for those suffering from this uncommon disease. For instance, in May 2023, Intercept Pharmaceuticals, Inc., a biopharmaceutical firm based in the United States, was granted orphan drug designation by the FDA for the combination of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a possible treatment for primary biliary cholangitis (PBC), a deteriorative liver disease, and obeticholic acid (sold as Ocaliva) has been approved for PBC in the United States.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

    How Is the Primary Biliary Cholangitis Market Conceptually Defined?

    Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive inflammation and destruction of the small bile ducts within the liver. This condition can lead to impaired bile flow, liver damage, and various related complications. PBC primarily affects middle-aged women and is often associated with symptoms such as fatigue, itching, and abdominal discomfort.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Primary Biliary Cholangitis Market Forecast 2025-2034: Growth Dynamics, Emerging Trends, and Strategic Opportunities

    Primary Biliary Cholangitis Market Forecast 2025-2034: Growth Dynamics, Emerging Trends, and Strategic Opportunities

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    Which Major Market Drivers Are Expected to Boost the Growth Potential of the Primary Biliary Cholangitis Market?

    The primary biliary cholangitis market is predicted to expand due to the rising rates of smoking. The process of inhaling and exhaling smoke from burned tobacco or similar substances, also known as smoking, is a recognized contributor to liver diseases such as PBC. As smoking rises, so does the number of individuals seeking treatment for liver-related problems. For example, in July 2023, Statistics Canada, a government organization, reported a 2.2% increase in cigarette production compared to June 2023. Moreover, cigarette sales increased by 2.6% to reach 1.4 billion units in June compared to May. Hence, increased smoking rates will boost the primary biliary cholangitis market. The primary biliary cholangitis market is also projected to grow due to an upsurge in liver cancer cases. Liver cancer, a disease that originates in the liver cells, is a significant risk factor for primary biliary cholangitis due to an increased risk of various cancers, including cholangiocarcinoma and hepatocellular carcinoma. The increasing incidence of this disease and its potential complications are expected to fuel the market’s growth. For example, in January 2024, the American Cancer Society predicted about 41,630 new liver cancer cases, with 28,000 cases in men and 13,630 in women. They also estimate that about 29,840 individuals (19,120 men and 10,720 women) are likely to die from this disease. Therefore, the rise in liver cancer cases is expected to stimulate the growth of the primary biliary cholangitis market.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

    #What is the Projected CAGR for the Primary Biliary Cholangitis Market Size from 2025 to 2034?

    The market size for primary biliary cholangitis has experienced swift growth in the previous years. A surge from $0.98 billion in 2024 to $1.09 billion in 2025 with a compound annual growth rate (CAGR) of 11.8% is projected. Factors such as heightened disease consciousness, an elevating global healthcare budget, strategic partnerships within the healthcare industry, an emphasis on patient advocacy, and governmental drives for liver health have fueled the growth during the historical period.

    Over the upcoming years, the market size for primary biliary cholangitis is anticipated to witness considerable growth, reaching $1.6 billion in 2029 with a compound annual growth rate (CAGR) of 9.9%. This surge during the predicted period is linked to the expansion of biomarker studies, global initiatives towards managing rare diseases, increased collaboration in clinical trials, and patient-focused healthcare strategies, along with the growing demand for liver transplants. The future trends include enhanced focus on non-invasive diagnostic methods, progress in biomarker research, emphasis on immunomodulatory treatments, application of artificial intelligence (AI), evaluations based on patient feedback in clinical trials, utilising telemedicine for patient care, focus on combination therapies, and the introduction of treatments targeting fibrosis.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520

    What Are the Key Market Innovations in thePrimary Biliary Cholangitis Market Over the Coming Years?

    Firms engaged in the primary biliary cholangitis market are concentrating their efforts on generating new and specific therapies, such as orphan drugs that include obeticholic acid (OCA) and bezafibrates to manage primary biliary cholangitis (PBC). The aim of designating the mixture of OCA and bezafibrate as an orphan drug is to offer a more encompassing and effective solution for PBC care, potentially enhancing the life of those struggling with this uncommon disease. For instance, in May 2023, Intercept Pharmaceuticals, Inc., an American biopharmaceutical enterprise, was acknowledged by the FDA with an orphan drug designation for the blend of obeticholic acid (OCA) and bezafibrate, a PPAR agonist. This is anticipated to serve as a viable treatment for primary biliary cholangitis (PBC), a steadily advancing liver disorder. Obeticholic acid, under the brand name Ocaliva, is already approved for PBC in the United States.

    Who Are the Top Companies Driving Innovation and Growth in thePrimary Biliary Cholangitis Market?

    Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

    Which Key Market Segments Comprise the Primary Biliary Cholangitis Market and Drive Its Revenue Growth?

    The primary biliary cholangitis market covered in this report is segmented –

    1) By Treatment Type: Drugs, Liver Transplantation

    2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

    3) By End-Users: Specialty Clinics, Homecare, Other End-Users

    Subsegments:

    1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

    2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

    Which Regions Are Emerging as Leaders in the Primary Biliary Cholangitis Market?

    North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2025, By The Business Research Company:

    Neuropathic Pain Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

    Pituitary Dwarf Treatment Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report

    Myelodysplastic Syndrome Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Primary Biliary Cholangitis Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities

    Primary Biliary Cholangitis Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    What key factors are powering the surge in the primary biliary cholangitis market right now?

    The primary biliary cholangitis market has seen rapid growth, expanding from $0.98 billion in 2024 to $1.09 billion in 2025, at a CAGR of 11.8%. Past growth was driven by increasing disease awareness, rising global healthcare expenditure, strategic collaborations, patient advocacy efforts, and government initiatives focused on liver health.

    How fast Is the primary biliary cholangitis market expected to grow, and what’s its future value?

    The primary biliary cholangitis market is expected to see strong growth, reaching $1.6 billion by 2029, with a CAGR of 9.9%. Growth will be driven by biomarker research, rare disease management efforts, clinical trial collaborations, patient-focused care, and rising liver transplant demand. Trends include biomarker advancements, non-invasive diagnostics, immunomodulatory therapy research, AI integration, patient-reported clinical outcomes, telemedicine, and combination therapies.

    Get your primary biliary cholangitis market report here!

    https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

    What are the leading drivers of growth in the primary biliary cholangitis market?

    The primary biliary cholangitis market is poised for growth, spurred on by the rising prevalence of smoking. This act entails the inhalation and exhalation of smoke from burning tobacco or other substances. It’s recognized that smoking is a risk factor for liver diseases, inclusive of PBC, and a rise in smoking will result in a greater number of people seeking healthcare for liver-related conditions. For example, government agency, Statistics Canada, reported that cigarette production in July 2023 witnessed an increase by 2.2% from June 2023, and there was a 2.6% uptick in cigarette sales in the same month, reaching 1.4 billion units. Therefore, the primary biliary cholangitis market is set to benefit from increasing smoking rates.

    Primary Biliary Cholangitis Market Driver: Increase in Liver Cancer Cases Boosts Growth in Primary Biliary Cholangitis Market

     

    What are the key segments defining the primary biliary cholangitis market?

    The primary biliary cholangitis market covered in this report is segmented –

    1) By Treatment Type: Drugs, Liver Transplantation

    2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

    3) By End-Users: Specialty Clinics, Homecare, Other End-Users

    Subsegments:

    1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

    2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

    Get your free sample now – explore exclusive market insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

    Who are the key players steering the development of the primary biliary cholangitis market?

    Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

    What emerging trends are influencing the growth of the primary biliary cholangitis market?

    Organizations operating within the primary biliary cholangitis market are aiming to carve out an exclusive niche for themselves by creating specialized and novel treatments. These include a mix of obeticholic acid (OCA) and bezafibrates, designated as orphan drugs, aimed specifically at tackling primary biliary cholangitis (PBC). The objective is to offer a comprehensive and superior method of managing PBC, increasing the potential to enhance the quality of life for those suffering from this uncommon disease. For instance, Intercept Pharmaceuticals, Inc., a biopharmaceutical entity from the US, was granted the status of an orphan drug by the FDA in May 2023. This was for the combined use of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a possible means of treating primary biliary cholangitis (PBC), a degenerative liver disease. The US has approved the use of obeticholic acid (known in the market as Ocaliva) for PBC treatment.

    Unlock exclusive market insights – purchase your research report now for a swift delivery!

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520

    Which regions are most influential in expanding the primary biliary cholangitis market?

    North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Similar Reports By The Business Research Company:

    Neuropathic Pain Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

    Pituitary Dwarf Treatment Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report

    Myelodysplastic Syndrome Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Primary Biliary Cholangitis Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities

    Primary Biliary Cholangitis Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    How Will the Growth Rate of the Primary Biliary Cholangitis Market Shape Industry Trends by 2034?

    The market size for primary biliary cholangitis has significantly expanded in the past few years. The growth is projected to continue from $0.98 billion in 2024 to $1.09 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. This expansion during the historic period is credited to enhanced disease recognition, escalated worldwide medical care spending, strategic alliances in the medical field, emphasis on patient representation, and governmental efforts towards liver health.

    In the coming years, it is predicted that the primary biliary cholangitis market will experience robust growth, expanding to $1.6 billion in 2029 with a compound annual growth rate (CAGR) of 9.9%. This growth during the predicted period is likely due to several factors such as the expansion of biomarker research, worldwide initiatives in managing rare diseases, increased partnerships in clinical trials, patient-oriented healthcare methodologies, and an escalating need for liver transplants. Significant trends for the forecast period entail advancement in biomarker research, an increased focus on non-invasive diagnostic methods, research emphasis on immunomodulatory therapies, the incorporation of artificial intelligence (ai), patient-reported results in clinical trials, the application of telemedicine for patient management, a focus on combination therapies, and upcoming therapies targeting fibrosis.

    What Major Innovations Are Driving the Accelerated Growth of the Primary Biliary Cholangitis Market?

    The primary biliary cholangitis market is poised for growth, spurred on by the rising prevalence of smoking. This act entails the inhalation and exhalation of smoke from burning tobacco or other substances. It’s recognized that smoking is a risk factor for liver diseases, inclusive of PBC, and a rise in smoking will result in a greater number of people seeking healthcare for liver-related conditions. For example, government agency, Statistics Canada, reported that cigarette production in July 2023 witnessed an increase by 2.2% from June 2023, and there was a 2.6% uptick in cigarette sales in the same month, reaching 1.4 billion units. Therefore, the primary biliary cholangitis market is set to benefit from increasing smoking rates.

    Primary Biliary Cholangitis Market Driver: Increase in Liver Cancer Cases Boosts Growth in Primary Biliary Cholangitis Market

     

    Get Your Free Sample of the Global Primary Biliary Cholangitis Market Report Now!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

    Who Are the Key Market Players Influencing the Growth of the Primary Biliary Cholangitis Industry?

    Major companies operating in the primary biliary cholangitis market report are:

    • Pfizer Inc._x000D_

    • F. Hoffmann-La Roche Ltd._x000D_

    • Merck And Co. Inc._x000D_

    • Novartis AG_x000D_

    • Bristol-Myers Squibb Company_x000D_

    What Key Market Trends Are Shaping the Future of the Primary Biliary Cholangitis Industry?

    Organizations operating within the primary biliary cholangitis market are aiming to carve out an exclusive niche for themselves by creating specialized and novel treatments. These include a mix of obeticholic acid (OCA) and bezafibrates, designated as orphan drugs, aimed specifically at tackling primary biliary cholangitis (PBC). The objective is to offer a comprehensive and superior method of managing PBC, increasing the potential to enhance the quality of life for those suffering from this uncommon disease. For instance, Intercept Pharmaceuticals, Inc., a biopharmaceutical entity from the US, was granted the status of an orphan drug by the FDA in May 2023. This was for the combined use of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a possible means of treating primary biliary cholangitis (PBC), a degenerative liver disease. The US has approved the use of obeticholic acid (known in the market as Ocaliva) for PBC treatment.

    Get Instant Access to the Global Primary Biliary Cholangitis Market Report with Swift Delivery!

    https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

    What Are the Main Segments of the Primary Biliary Cholangitis Market, and How Are They Evolving?

    The primary biliary cholangitis market covered in this report is segmented –

    1) By Treatment Type: Drugs, Liver Transplantation

    2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

    3) By End-Users: Specialty Clinics, Homecare, Other End-Users

    Subsegments:

    1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

    2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

    Which Regions Are Emerging as Leaders in the Primary Biliary Cholangitis Market?

    North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Defining Features of the Primary Biliary Cholangitis Market?

    Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive inflammation and destruction of the small bile ducts within the liver. This condition can lead to impaired bile flow, liver damage, and various related complications. PBC primarily affects middle-aged women and is often associated with symptoms such as fatigue, itching, and abdominal discomfort.

    Browse Through More Similar Reports By The Business Research Company:

    Neuropathic Pain Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

    Pituitary Dwarf Treatment Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report

    Myelodysplastic Syndrome Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: